Save the date for the Accelerate conference, August 22–25, 2023!

bars
times

Cheryl Arrowsmith

Medical Biophysics / University of Toronto /

Application Areas

Healthcare
Drugs

Bio

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto. Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles, and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018 and 2019. She was elected a AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

Research Interests

Publications

see all Publications
arrow-right
No items found.

Associated MAPs

see all Self-Driving Labs (MAPS)
arrow-right
No items found.

Related News

All News
arrow-right
No items found.